Ahrens Investment Partners’s Atossa Therapeutics ATOS Stock Holding History

Ahrens Investment Partners’s Portfolio ATOS Stock Details ATOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-667	Closed	-$16K	–	138
2019 Q4	$16K	Hold	667	–	–	0.01%	169
2019 Q3	$20K	Hold	667	–	–	0.01%	164
2019 Q2	$26K	Sell	667 -6,000	-90%	-$240K	0.01%	160
2019 Q1	$35K	Buy	+6,667	New	+$194K	0.02%	169

Other funds holding ATOS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return

Ahrens Investment Partners's ATOS Position: Q1 2020 in Review

Ahrens Investment Partners sold out of Atossa Therapeutics (ATOS) in Q1 2020, closing a stake of 667 shares — an estimated $16K sold.

Ahrens Investment Partners first reported a position in ATOS in Q1 2019 and held it in 4 quarters. The position peaked at $35K in Q1 2019. 10 funds tracked by Wall St. Rank hold ATOS as of Q1 2020.

Ahrens Investment Partners reported no remaining Atossa Therapeutics position as of Q1 2020 after selling out during the quarter.
Ahrens Investment Partners sold 667 Atossa Therapeutics shares in Q1 2020, an estimated $16K.
Ahrens Investment Partners first reported a position in Atossa Therapeutics in Q1 2019 and held it in 4 quarters.
Ahrens Investment Partners's Atossa Therapeutics position peaked at $35K in Q1 2019.
10 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q1 2020.

Based on Ahrens Investment Partners's 13F filing for Q1 2020, filed 24 Apr 2020.